Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 1,726 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at approximately $27,549,062.88. This represents a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Twist Bioscience Stock Down 3.1 %
Twist Bioscience stock traded down $1.28 during trading on Friday, reaching $40.30. The stock had a trading volume of 423,185 shares, compared to its average volume of 941,430. The stock has a market cap of $2.40 billion, a PE ratio of -11.92 and a beta of 2.15. The business has a 50 day moving average price of $45.30 and a 200 day moving average price of $45.31. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.75) earnings per share. On average, analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Van ECK Associates Corp grew its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the 3rd quarter valued at approximately $34,000. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000. Finally, US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the last quarter.
Wall Street Analyst Weigh In
TWST has been the subject of several analyst reports. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Robert W. Baird lifted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $54.40.
Get Our Latest Stock Report on Twist Bioscience
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
